Skip to main content

Table 1 Patient demographics and baseline characteristics (modified intention-to-treat population)

From: Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

  ApoE ε4 carrier study ApoE ε4 noncarrier study
Placebo (n = 431) BAP 0.5 (n = 650) Placebo (n = 328) BAP 0.5 (n = 255) BAP 1.0 (n = 253)
Mean age, years 70.2 70.9 69.7 71.1 70.7
Female, % 60.1 64.5 57.9 55.7 57.3
White, % 82.6 79.5 80.5 79.2 79.4
Asian, % 16.0 17.7 17.1 17.3 17.4
Black, % 0.7 0.8 0.6 0.8 2.0
Other, % 0.7 2.0 1.8 2.7 1.2
Mean duration of AD, years (SD) 2.9 (2.2) 3.0 (2.2) 2.8 (2.5) 2.6 (2.3) 2.9 (2.2)
ApoE ε4 allele status, n (%)      
 Heterozygous 334 (77.5) 500 (76.9)
 Homozygous 97 (22.5) 150 (23.1)
Using anti-AD medication at baseline, n (%) 386 (89.6) 578 (88.9) 274 (83.5) 204 (80.0) 209 (82.6)
Mean MMSE score (SD) 21.0 (3.0) 20.9 (3.1) 20.8 (3.1) 20.8 (3.2) 20.8 (3.1)
Mean years of formal education (SD) 12.5 (3.6) 12.2 (3.7) 11.8 (3.9) 11.9 (3.9) 11.8 (3.9)
Substudy participation, n (%)      
 vMRI + PET or vMRI + PET + CSF 47 (10.9) 64 (9.8) 34 (10.4) 27 (10.6) 21 (8.3)
 CSF or CSF + vMRI 104 (24.1) 160 (24.6) 67 (20.4) 44 (17.3) 53 (20.9)
 vMRI only 161 (37.4) 241 (37.1) 112 (34.1) 92 (36.1) 88 (34.8)
 No substudy 119 (27.6) 185 (28.5) 115 (35.1) 92 (36.1) 91 (36.0)
Mean ADAS-Cog/11 score (SD) 22.6 (8.9) 23.2 (8.9) 22.9 (10.2) 23.2 (10.0) 23.5 (9.3)
Mean DAD score (SD) 80.9 (18.7) 79.9 (18.3) 79.6 (17.9) 78.6 (20.0) 79.0 (18.4)
Infusions received, n (%)      
 1 13 (3.0) 34 (5.2) 40 (12.2) 22 (8.6) 29 (11.5)
 2 17 (3.9) 42 (6.5) 44 (13.4) 37 (14.5) 46 (18.2)
 3 29 (6.7) 57 (8.8) 36 (11.0) 31 (12.2) 25 (9.9)
 4 28 (6.5) 46 (7.1) 33 (10.1) 24 (9.4) 26 (10.3)
 5 43 (10.0) 98 (15.1) 40 (12.2) 35 (13.7) 30 (11.9)
 6 301 (69.8) 373 (57.4) 134 (40.9)a 106 (41.6) 97 (38.3)
  1. AD Alzheimer’s disease, ADAS-Cog/11 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale, ApoE apolipoprotein E, BAP bapineuzumab, CSF cerebrospinal fluid, DAD Disability Assessment for Dementia, MMSE Mini Mental State Examination, PET positron emission tomography, vMRI volumetric magnetic resonance imaging
  2. aOne patient in the placebo group received seven infusions